

## NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
<b>Insulins</b> <b>Rapid (analogue)</b> Immediate with food	<b>Apidra®</b> <b>Fiasp®</b> <b>Humalog®</b> (100,200) <b>Novorapid®</b>
<b>Insulins</b> <b>Short</b> 15 to 30 mins before food	<b>Actrapid®</b> <b>Humulin S®</b>
<b>Insulins</b> <b>Intermediate (Isophane)</b> Same time every day	<b>Humulin I®</b>
<b>Insulins</b> <b>Long (analogue)</b> Same time every day	<b>Abasaglar®</b> <b>Lantus®</b> <b>Toujeo®</b> <b>Tresiba®</b> (100,200)
<b>Insulins</b> <b>Biphasic</b> Up to 15 mins before food	<b>Humalog® Mix</b> (25,50) <b>Novomix® 30</b>
<b>Insulins</b> <b>Biphasic Isophane</b> Up to 30 mins before food	<b>Humulin® M3</b>
<b>Biguanides</b>	<b>1</b> <b>Metformin</b> tablets 500mg
<b>Sulfonylureas</b>	<b>1</b> <b>Gliclazide</b> tablets 40mg, 80mg
<b>Dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitors)</b>	<b>1</b> <b>Sitagliptin</b> tablets 25mg, 50mg, 100mg
	<b>2</b> <b>Linagliptin</b> tablets 5mg
<b>Glitazones (thiazolidinediones)</b>	<b>1</b> <b>Pioglitazone</b> tablets 15mg, 30mg, 45mg
<b>Sodium-glucose co-transporter 2 (SGLT-2) inhibitors</b>	<b>1</b> <b>Canagliflozin</b> 100mg, 300mg tablets
	<b>1</b> <b>Dapagliflozin</b> 10mg tablets
	<b>1</b> <b>Empagliflozin</b> 10mg, 25mg tablets
<b>GLP-1 mimetic (injectable)</b>  Prescribe by brand name	<b>1</b> <b>Daily injection</b> : liraglutide (Diaviv®) injection 6mg/mL 3ml pre-filled pens  <b>1</b> <b>Weekly injection:</b> Dulaglutide (Trulicity®) 0.75mg/0.5ml, 1.5mg/0.5ml, 3mg/0.5ml and 4.5mg/0.5ml solution for injection pre filled pens or <b>1</b> Semaglutide (Ozempic®) 0.25mg/0.19ml, 0.5mg/0.37ml, 1mg/0.74ml solution for injection pre-filled pens <b>1</b> <b>Oral tablets:</b> Semaglutide (Rybelsus®) 1.5mg, 4mg, 9mg tablets
<b>Treatment of hypoglycaemia</b>	<b>1</b> <b>Glucose (oral)</b> or <b>1</b> <b>Glucagen®</b> Hypokit 1mg powder and solvent for solution for injection (glucagon) <b>1</b> <b>Glucose intravenous infusion</b>

## NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
<b>Hypothyroidism</b>	<b>1</b> <b>Levothyroxine</b> tablets 25micrograms, 50micrograms, 100 micrograms
<b>Hyperthyroidism</b> <b>a) Antithyroid drugs</b> <b>b) Beta-blockers</b>	<b>1</b> <b>Carbimazole</b> tablets 5mg, 20mg <b>To be initiated on specialist advice</b> <b>1</b> <b>Propranolol</b> tablets 10mg, 40mg <b>1</b> <b>Propranolol</b> MR capsules 80mg, 160mg
<b>Corticosteroids</b> <b>a) Replacement therapy</b>	<u>Replacement therapy (mineralocorticoid)</u> <b>1</b> <b>Fludrocortisone</b> tablets 100micrograms <u>Glucocorticoid therapy</u> <b>Hydrocortisone</b> tablets 10mg
<b>b) Glucocorticoid therapy</b>	<b>1</b> <b>Prednisolone</b> tablets 1mg, 5mg or <b>1</b> <b>Dexamethasone</b> tablets 500micrograms, 2mg; injection 3.8mg/mL; injection 3.3mg/mL or <b>1</b> <b>Hydrocortisone</b> sodium succinate 100mg powder and solvent for solution for injection vials or <b>1</b> <b>Methylprednisolone</b> tablets 2mg, 4mg, 16mg, 100mg <b>1</b> <b>Methylprednisolone sodium succinate (Solu-Medrone®)</b> powder and solvent for injection vials 40mg, 125mg, 500mg, 1g <b>1</b> Intramuscular depot: <b>Methylprednisolone acetate</b> (Depo-Medrone®) suspension for injection vials 40mg/mL, 80mg/2mL, 120mg/3mL
<b>HRT for menopausal symptoms</b> <b>a) Women who have not had a hysterectomy</b>	<b>1</b> <u>Sequential combined (oral)</u> <b>Elleste-Duet®</b> 1mg, 2mg tablets (estradiol and norethisterone) or <b>Femoston®</b> 1/10, 2/10 tablets (estradiol and dydrogesterone) <b>1</b> <u>Sequential combined (transdermal)</u> <b>Evorel® Sequi</b> patches: (combination pack of 4 Evorel® 50 patches [estradiol 50micrograms/24hours] and 4 Evorel® Conti patches [estradiol 50micrograms/24hours]) and norethisterone acetate 170micrograms/24hours) <u>Continuous combined (oral)</u> <b>1</b> <b>Bijuve®</b> 1mg/100mg capsules ( estradiol 1mg and progesterone 100mg) <b>1</b> <b>Femoston® conti</b> 0.5mg/2.5mg tablets; 1mg/5mg tablets (estradiol and dydrogesterone) <b>1</b> <b>Indivina®</b> 1mg/2.5mg tablets;1mg/5mg tablets; 2mg/5mg tablets (estradiol and medroxyprogesterone acetate) <i>Note: only licensed when LMP occurred over 3 years previously</i> <b>1</b> <b>Klifem®</b> tablets (estradiol 2mg and norethisterone 1mg)

## NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
	<p>① <b>Kliovance</b>® tablets (estradiol 1mg and norethisterone 500micrograms)</p> <p><u>Continuous combined (transdermal)</u></p> <p>① <b>Evorel</b>® <b>Conti patches</b> (estradiol 50micrograms/24hours and norethisterone 170micrograms/24hours (matrix patch))</p>
<b>b) Women who have had a hysterectomy or who have a suitable levonorgestrel intrauterine system (LNG IUS) in situ for &lt; 5 years</b>	<p><u>Unopposed oestrogens (oral)</u></p> <p>① <b>Elleste-Solo</b>® 1mg, 2mg (estradiol) tablets or <b>Zumenon</b>® 1mg, 2mg (estradiol) tablets</p> <p><u>Unopposed oestrogens (transdermal)</u></p> <p>① <b>Evorel</b>® patches 50micrograms (or 25micrograms, 75micrograms, 100micrograms/24 hours) (estradiol)</p> <p><u>Unopposed oestrogens spray</u></p> <p>① <b>Lenzetto</b>® 1.53mg/dose transdermal spray</p> <p><u>Unopposed oestrogens gel</u></p> <p>① <b>Oestrogel</b>® 0.06% gel or</p> <p>① <b>Sandrena</b>® gel sachets 500mcg, 1mg</p>
<b>Drugs for the treatment and management of Osteoporosis</b> <b>(a) Calcium and Vitamin D</b>  <b>(b) bisphosphonates</b>	<p>① <b>Adcal-D3</b>® Caplets (750mg/200IU) or</p> <p>① <b>Accrete D3</b>® film-coated tablets (600mg/400IU) or</p> <p>① <b>Accrete D3</b>® One a Day Chewable Tablets (1000 mg / 880 IU)</p> <p>② <b>Adcal-D3</b>® Dissolve effervescent tablets (1500mg /400IU) <i>Reserve for swallowing difficulties</i></p> <p>① <b>Alendronic acid</b> tablets 70mg or</p> <p>① <b>Risedronate sodium</b> tablets 35mg</p>
<b>Acromegaly</b>	<p>The primary treatment of acromegaly is usually pituitary surgery. Management and treatment requires specialist involvement. Please refer to 'Prescribing Notes' in full version of formulary.</p>